Control of nasal obstruction in perennial allergic rhinitis

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 3, 2004, Pages 165-170

  Wang, De Yun ^a,d   Raza, Tanveer ^a   Gordon, Bruce R ^b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b HARVARD UNIVERSITY   (United States)

^c CAPE COD HOSPITAL   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Acoustic rhinometry; International guidelines; Nasal obstruction; Persistent (perennial) allergic rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; CHROMONE DERIVATIVE; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LEUKOTRIENE RECEPTOR BLOCKING AGENT;

CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL PRACTICE; HEALTH CARE COST; HUMAN; IMMUNOTHERAPY; IN SITU HYBRIDIZATION; MEDIATOR RELEASE; NOSE MUCOSA; NOSE OBSTRUCTION; OCCUPATIONAL HAZARD; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PERENNIAL RHINITIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REBOUND; REVIEW; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VASODILATATION;

CHROMONES; GLUCOCORTICOIDS; HISTAMINE H1 ANTAGONISTS; HUMANS; IMMUNOTHERAPY; LEUKOTRIENE ANTAGONISTS; NASAL DECONGESTANTS; NASAL OBSTRUCTION; RHINITIS, ALLERGIC, PERENNIAL; SPORTS;

EID: 2542478008     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/00130832-200406000-00005     Document Type: Review

References (44)

1. Jessen M, Malm L. Definition, prevalence and development of nasal obstruction. Allergy 1997; 52 (Suppl 40):3-6.
2. Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its Impact on Asthma (ARIA) (ARIA Workshop Report). J Allergy Clin Immunol 2001; 108 (Suppl):S147-S334.
3. Wang DY, Niti M, Smith JD, et al. Rhinitis: do diagnostic criteria affect the prevalence and treatment? Allergy 2002; 57:150-154.
4. Wang DY, Clement P, Smitz J, et al. Correlations between complaints, inflammatory cells and mediators after nasal allergen challenge and during natural allergen exposure. Int Arch Allergy Immunol 1995; 106:278-285.
5. Wang D, Clement P. Assessment of early and late-phase nasal obstruction in atopic patients after nasal allergen challenge. Clin Otolaryngol 1995; 20:368-373.
6. Huang ZL, Ong KL, Goh SY, et al. Assessment of nasal cycle by acoustic rhinometry and rhinomanometry. Otolaryngol Head Neck Surg 2003; 128:510-516. This paper demonstrates in details the pattern, frequency and amplitude of nasal cycles in healthy subjects and in patients with perennial allergic rhinitis.
7. Clement PA. Committee report on standardization of rhinomanometry. Rhinol 1984; 22:151-155.
8. Hilberg O, Jackson AC, Swift DL, Pedersen OF. Acoustic rhinometry: evaluation of nasal cavity geometry by acoustic reflection. J Appl Physiol 1989; 66:295-303.
9. Suzina AH, Hamzah M, Samsudin AR. Objective assessment of nasal resistance in patients with nasal disease. J Laryngol Otol 2003; 117:609-613. This study investigated the association between the results of active anterior rhinomanometry measurement and subjective nasal obstruction complaints.
10. Chan KO, Huang ZL, Wang de Y. Acoustic rhinometric assessment of nasal obstruction after treatment with fluticasone propionate in patients with perennial rhinitis. Auris Nasus Larynx 2003; 30:379-383. This study demonstrated the effect of fluticasone propionate on nasal obstruction and the relationship between subjective symptoms (VAS) and objective measurements of nasal cavity dimensions (acoustic rhinometry) before and after treatment.
11. Wang DY, Raza MT, Goh YT, et al. Acoustic rhinometry in nasal allergen challenge study: which dimensional measures are meaningful? Clin Exp Allergy; (in press).
12. Terreehorst I, Hak E, Oosting AJ, et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N Engl J Med 2003; 349:237-246. This was a well-controlled large sample study on the effect of allergen avoidance using a mattress encasement in clinical outcomes of PAR in The Netherlands.
13. 1 antihistamine (levocetirizine) on PAR symptoms (including nasal obstruction).
14. 1 antihistamine (destoratatine) on symptoms of allergic rhinitis (including nasal obstruction).
15. Shelton D, Eiser N. Histamine receptors in the human nose. Clin Otolaryngol 1994; 19:45-49.
16. Wang DY, Clement P, Smitz J. Effect of H1 and H2 antagonists on nasal symptoms and mediator release in atopic patients after nasal allergen challenge during the pollen season. Acta Otolaryngol (Stockh) 1996; 116:91-96.
17. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003; 58:380-385. Improvement of nasal obstruction and associated quality of life in PAR patients after IGC treatment.
18. Bachert C, El-Akkad T. Patient preferences and sensory comparisons of three intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89:292-297.
19. Bunnag C, Suprihati D, Wang DY. Patient preference and sensory perception of three intranasal glucocorticosteroids for allergic rhinitis. Clin Drug Invest 2003; 23:39-44. A double-blind, comparative, crossover study of medication preference, sensory perceptions and compliance of allergic rhinitis patients after a single administration of three intranasal glucocorticosteroids (an Asian study).
20. Loh CY, Chao SS, Chan YH, Wang DY. A clinical survey on compliance in the treatment of rhinitis using nasal steroids. Allergy; (in press).
21. Wang D-Y, Chan A, Smith JD. Management of allergic rhinitis: a common part of practice in primary care clinics. Allergy 2004; 59:315-319.
22. Ciprandi G, Frati F, Marcucci F, et al. Nasal cytokine modulation by montelukast in allergic children: a pilot study. Allerg Immunol (Paris) 2003; 35:295-299. This paper investigates the effect of a leukotriene antagonist (montelukast) in treatment of PAR and asthma in children and its antiinflammatory effect on T helper type 1 and T helper type 2 cytokine polarization.
23. Shirasaki H, Kanaizumi E, Watanabe K, et al. Expression and localization of the cysteinyl leukotriene 1 receptor in human nasal mucosa. Clin Exp Allergy 2002; 32:1007-1012.
24. Ueda T, Takeno S, Furukido K, et al. Leukotriene receptor antagonist pranlukast suppresses eosinophil infiltration and cytokine production in human nasal mucosa of perennial allergic rhinitis. Ann Otol Rhinol Laryngol 2003; 112:955-961. Theses authors describe the antiinflammatory effect of a leukotriene receptor antagonist (pranlukast) on eosinophil infiltration and cytokine production in human nasal mucosa.
25. Furukido K, Takeno S, Ueda T, et al. Suppression of the Th2 pathway by suplatast tosilate in patients with perennial nasal allergies. Am J Rhinol 2002; 16:329-336.
26. van Adelsberg J, Philip G, Pedinoff AJ, et al. Montelukast improves symptoms of seasonal allergic rhinitis over a 4-week treatment period. Allergy 2003; 58:1268-1276. Montelukast is superior to antihistamines in relieving nasal obstruction in patients with allergic rhinitis.
27. Parnes SM. The role of leukotriene inhibitors in allergic rhinitis and paranasal sinusitis. Curr Allergy Asthma Rep 2002; 2:239-244.
28. Ratner PH, Ehrlich PM, Fineman SM, et al. Use of intranasal cromolyn sodium for allergic rhinitis. Mayo Clin Proc 2002; 77:350-354.
29. Graif Y, Goldberg A. The efficacy of nasal surgery among patients with and without allergies. Allergy Asthma Proc 2003; 24:119-122. This describes a 1-year follow-up clinical study that investigated the clinical efficacy of turbinate reduction in treating nasal obstruction of patients with PAR.
30. Fradis M, Malatskey S, Magamsa I, Golz A. Effect of submucosal diathermy in chronic nasal obstruction due to turbinate enlargement. Am J Otolaryngol 2002; 23:332-336.
31. Ogino-Nishimura E, Okamura HO, Takiguchi Y. Argon plasma coagulation for intractable nasal obstruction occurring in patients with allergic rhinitis. Fukushima J Med Sci 2003; 49:15-22. This study introduced a new surgical treatment for intractable nasal obstruction in patients with nasal allergy by using the argon plasma coagulator.
32. Supiyaphun P, Aramwatanapong P, Kerekhanjanarong V, Sastarasadhit V. KTP laser inferior turbinoplasty: an alternative procedure to treat the nasal obstruction. Auris Nasus Larynx 2003; 30:59-64. This describes the effect of potassium-titanyl-phosphate laser inferior turbinoplasty in successfully treating nasal obstruction and other allergic rhinitis symptoms.
33. Takeno S, Osada R, Ishino T, Yajin K. Laser surgery of the inferior turbinate for allergic rhinitis with seasonal exacerbation: an acoustic rhinometry study. Ann Otol Rhinol Laryngol 2003; 112:455-460. The authors report an improvement of subjective and objective symptoms of nasal obstruction using laser turbinectomy.
34. Passali D, Passali FM, Damiani V, et al. Treatment of inferior turbinate hypertrophy: a randomized clinical trial. Ann Otol Rhinol Laryngol 2003; 112:683-688. This is a randomized comparative clinical study on long-term efficacy of different surgical techniques in treating turbinate hypertrophy. Results showed that submucosal resection was found to be most beneficial in terms of nasal patency, mucociliary clearance and physiologic local secretory immunoglobulin A production.
35. Schmelzer B, Katz S, Vidts G. Long-term efficacy of our surgical approach to turbinate hypertrophy. Am J Rhinol 1999; 13:357-361.
36. Haydon RC, Gordon BR. Immunotherapy. In: Krouse JH, Chadwick SJ, Gordon BR, Derebery MJ, editors. Allergy and immunology, an otolaryngic approach. New York: Lippincott; 2002. pp. 151-184.
37. Saltoun CA. Update on efficacy of allergen immunotherapy for allergic rhinitis and asthma. Allergy Asthma Proc 2002; 23:377-380.
38. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003; (2):CD002893. This Cochrane database study evaluated the efficacy of sublingual immunotherapy in reducing rhinitis symptoms and the use of medication in adult patients with allergic rhinitis.
39. Allen DB, Meltzer EO, Lemanske RF Jr, et al. No growth suppression in children treated with the maximum recommended dose of fluticasone propionate aqueous nasal spray for one year. Allergy Asthma Proc 2002; 23:407-413.
40. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003; 90:56-62. This was a double-blind randomized study on safety and efficacy of long-term IGC (intranasal triamcinolone acetonide and intranasal fluticasone propionate) treatment in children with PAR.
41. Moller C, Ahlstrom H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003; 33:816-822. This was a double-blind randomized study of long-term efficacy and safety of treatment with IGC (budesonide) in children with PAR.
42. Lai DS, Lue KH, Hsieh JC, et al. The comparison of the efficacy and safety of cetirizine, oxatomide, ketotifen, and a placebo for the treatment of childhood perennial allergic rhinitis. Ann Allergy Asthma Immunol 2002; 89:589-598.
43. Gani F, Braida A, Lombardi C, et al. Rhinitis in pregnancy. Allerg Immunol (Paris) 2003; 35:306-313. This paper reviews the clinical data on the incidence, underlying mechanisms and safety treatment of nasal obstruction in women during pregnancy.
44. Blaiss MS. Food and Drug Administration (U.S.). ACAAI-ACOG (American College of Allergy, Asthma, and Immunology and American College of Obstetricians and Gynecologists.) Management of rhinitis and asthma in pregnancy. Ann Allergy Asthma Immunol 2003; 90 (Suppl 3):16-22. This describes the importance and treatment choices of allergic rhinitis in pregnancy.